ONO-4538 Phase II Rollover Study (ONO-4538-98)
ConditionPan-tumor
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age16+
SponsorOno Pharmaceutical Co., Ltd.
About this trial
This study is intended to confirm the long-term safety of ONO-4538 in pan-tumor participants being treated with ONO-4538 monotherapy or in Combination with Other Therapies in clinical trials.
Eligibility criteria
Qualifiers
Participant who is being treated with ONO-4538 as monotherapy or in Combination with Other Therapies in clinical trials
Participant who is eligible for ONO-4538 monotherapy or in combination with other therapies as per the clinical trials, and/or investigator-assessed clinical benefit
Disqualifiers
Participant judged to be incapable of providing consent for reasons such as concurrent dementia
Participant judged by the investigator to be inappropriate as participants of this study
Trial design
Treatments tested in this trial
- ONO-4538
- oxaliplatin
- S-1
- capecitabine
- bevacizumab
- temozolomide
Treatment groups
59 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov